Literature DB >> 15003906

Incidence of pulmonary hypertension in patients with chronic myeloproliferative disorders.

Vasilia Garypidou1, Sofia Vakalopoulou, Dimokritos Dimitriadis, Konstantinos Tziomalos, George Sfikas, Vasilios Perifanis.   

Abstract

Entities:  

Mesh：

Year:  2004        PMID： 15003906

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  20 in total

1.  Impaired right ventricular-pulmonary vascular function in myeloproliferative neoplasms.

Authors:  Emir C Roach; Margaret M Park; W H Wilson Tang; James D Thomas; Kewal Asosingh; Matt Kalaycio; Serpil C Erzurum; Samar Farha
Journal:  J Heart Lung Transplant       Date:  2014-09-28       Impact factor: 10.247

2.  Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis.

Authors:  Rohan Gupta; Faizi Jamal; Dongyun Yang; Chendri Chendri; Ibrahim Aldoss; Monzr Al Malki; Matthew Mei; Amandeep Salhotra; Surime Dobrin; Michael Tran; K Venkataraman; Joycelynne Palmer; Anthony S Stein; Karamjeet Sandhu; Samer Khaled; Ahmed Aribi; Guido Marcucci; Stephen J Forman; David Snyder; Ryotaro Nakamura; Haris Ali; Vinod Pullarkat
Journal:  Bone Marrow Transplant       Date:  2019-11-06       Impact factor: 5.483

3.  Prevalence and risk factors of high echocardiographic probability of pulmonary hypertension in myeloproliferative neoplasms patients.

Authors:  Yanika Jindamai; Ekarat Rattarittamrong; Arintaya Phrommintikul; Lalita Yongsmith; Pokpong Piriyakhuntorn; Thanawat Rattanathammethee; Sasinee Hantrakool; Chatree Chai-Adisaksopha; Adisak Tantiworawit; Lalita Norasetthada
Journal:  Int J Hematol       Date:  2020-07-23       Impact factor: 2.490

4.  Hypoxia-inducible factors in human pulmonary arterial hypertension: a link to the intrinsic myeloid abnormalities.

Authors:  Samar Farha; Kewal Asosingh; Weiling Xu; Jacqueline Sharp; Deepa George; Suzy Comhair; Margaret Park; W H Wilson Tang; James E Loyd; Karl Theil; Raymond Tubbs; Eric Hsi; Alan Lichtin; Serpil C Erzurum
Journal:  Blood       Date:  2011-01-21       Impact factor: 22.113

5.  Incidence of pulmonary hypertension in patients with chronic myeloproliferative disorders.

Authors:  Ranju Gupta; Sirisha Perumandla; Yelena Patsiornik; Selvanayagam Niranjan; Anju Ohri
Journal:  J Natl Med Assoc       Date:  2006-11       Impact factor: 1.798

Review 6.  Group 5 Pulmonary Hypertension: The Orphan's Orphan Disease.

Authors:  Sara Kalantari; Mardi Gomberg-Maitland
Journal:  Cardiol Clin       Date:  2016-08       Impact factor: 2.213

Review 7.  Pulmonary hypertension associated with chronic hemolytic anemia and other blood disorders.

Authors:  Roberto F Machado; Harrison W Farber
Journal:  Clin Chest Med       Date:  2013-10-17       Impact factor: 2.878

Review 8.  Dasatinib-induced pulmonary arterial hypertension.

Authors:  Nurgül Özgür Yurttaş; Ahmet Emre Eşkazan
Journal:  Br J Clin Pharmacol       Date:  2018-03-06       Impact factor: 4.335

9.  Incremental Utility of Right Ventricular Dysfunction in Patients With Myeloproliferative Neoplasm-Associated Pulmonary Hypertension.

Authors:  Jiwon Kim; Spencer Krichevsky; Lola Xie; Maria Chiara Palumbo; Sara Rodriguez-Diego; Brian Yum; Lillian Brouwer; Richard T Silver; Andrew I Schafer; Ellen K Ritchie; Maria Mia Yabut; Claudia Sosner; Evelyn M Horn; Richard B Devereux; Joseph M Scandura; Jonathan W Weinsaft
Journal:  J Am Soc Echocardiogr       Date:  2019-10-03       Impact factor: 5.251

10.  Circulating angiogenic precursors in idiopathic pulmonary arterial hypertension.

Authors:  Kewal Asosingh; Micheala A Aldred; Amit Vasanji; Judith Drazba; Jacqueline Sharp; Carol Farver; Suzy A A Comhair; Weiling Xu; Lauren Licina; Lan Huang; Bela Anand-Apte; Mervin C Yoder; Rubin M Tuder; Serpil C Erzurum
Journal:  Am J Pathol       Date:  2008-02-07       Impact factor: 4.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.